Results
We identified 186 patients who received rituximab between 2011 and 2020
at our Institution, of whom, 94 met the study eligibility criteria.
Patients with histologically unproven B-NHL (n=4), non-B-NHL (n=8),
indolent B-NHL (n=76) or high-grade B-NHL who only received a single
dose of rituximab (n=4), either because of reaction at infusion (n=3) or
cardiac arrhythmia (n=1) were excluded from this analysis (Figure 1).